RE:RE:RE:RE:2nd ADC toxicity summit
Lee430 wrote: I didn't word that correctly, what I was trying to find out is if that 10:00 a.m. slot is a good slot as it seems their other presentations weren't exactly prime time.
Mannequin wrote: correct 10am
Lee430 wrote: Scarlet1967, I noticed Thera’s time slot (10AM on day one) and it appears to be a decent one, is that correct?
scarlet1967 wrote: https://storage.pardot.com/448062/1713868707LeQ1wadz/HW240322_46355_2nd_ADC_Toxicity_Summit_brochure_v8.pdf
"Targeting Sortilin (SORT1) to Unlock the Potential of Peptide Drug Conjugates (PDCs) in Oncology: Rapid Internalization within Minutes w
Unique Multimodal MOA & Safety Profile
- Understand the rationale for targeting the SORT1 receptor in cancer
- Discuss the unique toxicity profile of sudocetaxel zendusortide (TH1902), the lead PL from Theratechnologies' SORT1+ Technology ™ platform, that differs substantially fro the safety profile of taxanes, due to the multimodal MOA of the conjugate and the low levels of free circulating docetaxel
- Discuss how this multifaceted MOA with improved safety profile can lead to prolonge regression of disease and enable combinations with ADCs, PDCs and other anti-can therapies
- Discuss the ongoing phase I clinical development of sudocetaxel zendusortide, focus on dose optimization"
So Christian is speaking at this summit this time the focus is toxicity/ safety profile of the drug!
Have they had more human data so far as the issue with the drug and abrupt stop of the clinical trial initially was because of toxicity/safety concerns??
The time is ok, this summit seems to be exploring multiple aspects of toxicity both in vivo and in clinical settings. Christian's presentation seems to be focused on the in vivo part however he is going to elaborate about the dose optimization in the part3 of phase1. The question is since the first patient was dosed on the higher level on or before March 21st and the second on or just before April 3rd and the third one was undergoing screening (that's what they said during the earning call) around the same time and now they are partnering up with ADC toxicity summit... does all the above indicate that they had so far no safety/toxicity issues?? Another thing is it seems they are now trying to sell a broader product covering the preclinical findings, various therapeutic potential combinations and the potentials of the clinical aspects of the Sort1 platform with the optimized dosing process. Note the idea of the phase 1 is primarily to find the MTD and potential primary efficacy anything more than that will just add value to the clinical program among investors and potential partners and this is I believe we all are hoping for.